We have vast experience supporting the P&MA launch strategy of high-profile brands and can help clients solve highly nuanced problems (i.e. HUB financial assistance program, HRU model.)
Showing 5 of 35 posts
September 1, 2021 | Blogs
CBPartners reviews the COVID-driven changes to patients, providers, payers, clinical research, and pharmaceutical distribution within the US.
August 2, 2021 | Blogs
A CMS regulation from the Trump Administration requires hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021, with the rule still being widely ignored by hospitals.
July 20, 2021 | Podcasts
The biosimilar market is booming across the EU, Latin America and Asia Pacific regions. In this next episode of the multi-part biosimilar series, CBPartners’ regional Centers of Excellence teams provide expert insights into the trends and dynamics of the biosimilar market, with a particular focus on these regions.
March 8, 2021 | Podcasts
This episode, which kicks off season two of CBPartners’ Pharma Take-away, discusses the possible evolution of healthcare and healthcare policy in the United States, and explores the changes we may expect over the next few years as a result of the presidential election party transition.
February 19, 2021 | Infographics
KAISER Integrates DTx Into the Behavioral Health Treatment Paradigm at No Extra Cost After a Clinician Referral
KAISER’s recent systemic integration of digital health therapeutics (DTx) into the treatment paradigm for behavioral health concerns is a step towards modernizing healthcare and represents a very structured approach to real-world data generation.